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INTRODUCTION
Hepatocellular carcinoma may develop from multistep 
carcinogenesis via dysplastic nodules in the cirrhotic liver. The 
first stage between high-grade dysplastic nodule to overt hepa-
tocellular carcinoma is vaguely nodular, early hepatocellular 
carcinoma. The consensus on the nomenclature and pathologic 
characteristics of both entities were recently established by an 
international consensus group for hepatocellular neoplasia,
1 and 
were adopted in the recent World Health Organization series of 
tumor classification.
2
We present herein a case of early hepatocellular carcinoma in 
a 58-year-old man with B-viral macronodular cirrhosis. We 
discuss the histopathologic features and differential diagnosis 
from high-grade dysplastic nodule of the liver.
CASE SUMMARY
A 58-year-old male was transferred to our hospital for surgery 
to remove a recently found liver mass. The liver nodule was 
found on abdominal ultrasound during a regular checkup. The 
hepatocellular carcinoma was suspected after subsequent 
abdominal computed tomography (CT) at a private clinic.
The initial hematologic and blood chemistry data were as 
follows: white blood cell count, 6,000/μL; hemoglobin, 14.6 g/dL; 
platelet count, 81,000/μL; blood urea nitrogen, 13 mg/dL; 
creatinine, 0.7 mg/dL; albumin, 3.5 g/dL; aspartate aminotrans-
ferase, 44  IU/L; alanine aminotransferase, 32  IU/L; and total 
bilirubin, 0.8 mg/dL. He was positive for hepatitis B surface 
antigen (HBsAg) and anti-hepatitis B envelop (HBe), and 
negative for anti-HBs, HBeAg, and hepatitis C virus. His 
alpha-fetoprotein and cancer antigen 19-9 levels were elevated, 
at 20.4 ng/mL and 65.3 U/mL, respectively. He was negative for 
both protein- induced by vitamin K absence or antagonist II and 
carcinoembryonic antigen, 21 mAU/mL and 0.6 ng/mL, respectively. 
The preoperative work-up revealed a slightly enhancing and 
delayed washout nodule of about 1.1 cm in segment (S) 6 of the 
liver on liver dynamic magnetic resonance imaging with 
enhancement. It was not well delineated on T1- or T2-weighted 
images and exhibited opposing signal intensities on in and out 
phases. Hepatocellular carcinoma was suspected, and a S6 
segmentectomy was performed.
PATHOLOGY FINDINGS
The resected portion of the left liver weighed 82 g and 
measured 10×6×3.5  cm. Gleason’s capsule was smooth and 
intact. Sectioning revealed an ill-defined, vaguely nodular, and 
somewhat yellow-brown solid mass measuring 1.2×1.0  cm 
(Fig. 1). The surrounding liver parenchyma had been replaced by 
large cirrhotic nodules. Microscopic examination of the nodule 
disclosed proliferation of well-differentiated hepatocytes in a 
microtrabecular pattern, accompanied by diffuse macrovesicular 
fatty metamorphosis (Fig. 2). The hepatic cords were irregular in 
arrangement, and on average, two cells thick. They spread 
laterally in a replacing growth pattern without a surrounding So-Young Jin, et al. Early hepatocellular carcinoma  239
Figure 2. Low-power view of the liver mass. Diffuse fatty change 
is evident throughout the nodule (H-E, ×12.5).
Figure 1. Cut surface of the liver. An ill-defined, vaguely nodular, 
solid, yellow-to-brown nodule with a largest dimension of 1.2 cm
is seen against the cirrhotic background.
 
Figure 3. Microscopic findings of the liver mass. (A) A replacing growth of microtrabecular pattern is observed without a tumor capsule. 
A few portal tracts are noted in the lower portion. (B) The nuclear density is increased to more than twice that of the surrounding 
nonneoplastic liver (A: H-E, ×100; B: H-E, ×400).
tumor capsule or pseudocapsule. Residual portal tracts could be 
observed within the nodule (Fig. 3A). The nuclear density was 
variably increased, mostly more than twice that of normal 
hepatocytes. The cell size was constant, but smaller than usual 
and with an increased nuclear cytoplasmic ratio, consistent with 
small-cell change (Fig. 3B). A few foci of stromal invasion were 
noted within and around the portal tract (Fig. 4A). These findings 
were highlighted by immunohistochemistry for cytokeratin 7 
(Fig. 4B). Sinusoidal capillarization was not evident and was 
rather focally localized in the periphery of the dysplastic portion. 
Foci of portal vein invasion was not found.
DISCUSSION
Ultrasound screening allows the early detection of small 
hepatocytic lesions, and the progress of radiologic techniques 
has meant that pathologists experience a greater number of 
smaller lesions in the liver. Any hepatocytic nodules in cirrhotic 
liver tissue, including large regenerative nodules, low-grade 
dysplastic nodules, high-grade dysplastic nodules, and small 
hepatocellular carcinomas, can present similarly. A small hepato-
cellular carcinoma is defined as being less than 2 cm in diameter, 
and can be divided into two types: vaguely nodular early 
hepatocellular carcinoma and distinctly nodular progressed 
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Figure 4.  Microscopic findings of stromal invasion. (A) A focus of tumor cell invasion can be seen within an intratumoral portal 
tract. (B) This is not associated with ductular reaction on immunohistochemistry (A: H-E, ×200; B: cytokeratin 7, ×200).
hepatocellular carcinoma. Early hepatocellular carcinoma 
cannot be easily differentiated from the high-grade dysplastic 
nodules on either macroscopic or microscopic examination. 
Although there are some differences in nuclear density (1.3-2 
times greater in high-grade dysplastic nodules vs. 2 times greater 
in hepatocellular carcinoma than in adjacent hepatocytes), the 
two lesion types share many common features, such as an 
indistinct margin, no capsule, increased cell density, irregular 
thin-trabecular pattern, intratumoral portal tracts, pseudoglandular 
pattern, diffuse fatty change, nodule-in-nodule appearance or 
subnodules with an increased Ki-67 proliferation index, and 
varying numbers of unpaired arteries or a varying extent of 
sinusoidal capillarization.
3 Masking of the cytologic atypia of 
malignant cells by fatty change renders it more difficult to 
recognize them. The characteristic features of definite malignancy 
seen in progressed hepatocellular carcinoma, such as portal 
vein invasion or metastasis, are not usually seen in early 
hepatocellular carcinoma.
3 The only convincing helpful finding 
of malignancy in early hepatocellular carcinoma is stromal 
invasion.
1-3
Stromal invasion is invasion of tumor cells into the intra-
tumoral portal tracts. The liver is different from other organ sites, 
which have a well-developed basement membrane structure, and 
because of this anatomic difference, the foci of destruction of the 
stromal-parenchymal interface must be recognized by invading 
growth. The identification of stromal invading foci is not easy 
and can be frequently missed in needle biopsy of the liver, where 
the portal tracts might not be included in the small specimen, 
although it can be assisted by special staining or immunohisto-
chemistry. Victoria blue or reticulin stains help to discriminate 
the residual portal tracts, while imunohistochemical stains for 
cytokeratin 7 and 19 can help to determine whether the equivocal 
lesion of stromal invasion is true tumor cell invasion or ductular 
reaction of pseudoinvasion around nonmalignant nodules.
4
Other biomarkers have been applied to the differential 
diagnosis of high-grade dysplastic nodule from well-differentiated 
hepatocellular carcinoma. A panel of triple immunohistochemical 
markers－glypican-3, heat shock protein 70 (HSP70), and glutamine 
synthetase (GS)－can increase the sensitivity and specificity to 
72% and 100%, respectively, in cases where there is positivity 
for any two markers.
5 However, it is recognized that the 
interpretation of theses markers should be made with caution, 
and some helpful tips have been suggested. The characteristic 
staining pattern of glypican-3 is usually focal cytoplasmic 
staining; its application as a sole marker of malignancy is thus 
not recommended, and it should be remembered that it can yield 
a positive reaction in other lesions and in regenerating hepatocytes. 
HSP70 can be approved in cases of simultaneous positivity in 
both the nucleus and cytoplasm, with the internal positive control 
of hepatobiliary cells of ductular reactions. GS should be 
accepted in cases of diffuse, intense positivity because of the 
stepwise increasing pattern from dysplastic nodules through to 
well-differentiated hepatocellular carcinoma and further to 
poorly differentiated hepatocellular carcinoma. Another, recently 
introduced marker, clathrin heavy chain, reportedly exhibits a 
very promising specificity and positive predictive value.
6 
However, there is no perfect single marker or panel that allows a 
confirmative diagnosis of malignancy.
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The use of these markers may help to discriminate the equivocal 
nodule, but may also lead to false confidence, particularly in the 
case of limited samples, such as those obtained by needle biopsy. 
Therefore, a final decision of early hepatocellular carcinoma can 
only be drawn on the basic findings of routine hematoxylin- 
and-eosin staining, such as abnormal-appearing cytologic and 
architectural findings, with meticulous effort to find the foci of 
stromal invasion.
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